New guidance to aid cost-effectiveness analysis of new drugs
By Catherine Eckford (European Pharmaceutical Review)
Lilly IBD biologic receives expanded US approval
By Catherine Eckford (European Pharmaceutical Review)
Long-term potential revealed for novel modifier gene therapy
By Catherine Eckford (European Pharmaceutical Review)
Potential blockbuster drugs to watch in 2025
By European Pharmaceutical Review
Hydrogel encapsulation: unlocking the potential of cell therapies for targeted…
By Francis Karanu (Likarda), Stephen Harrington (Likarda)
The year ahead for RNA therapeutic development and manufacturing
By Dr Kate Broderick (Maravai Life Sciences and TriLink Biotechnologies)